AbbVie to acquire Apogee Therapeutics for $135.11/share, ~$10.9B equity value

Apogee Therapeutics, Inc.

AbbVie to acquire all outstanding shares of Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
Acquisition expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
Apogee's lead asset zumilokibart (APG777) targets IL-13 for atopic dermatitis; APG273 targets IL-13/TSLP for asthma.
Voting agreement with certain stockholders to support merger; termination fee of $381.3M payable under specified conditions.

item 1.01 item 5.07 item 7.01 item 8.01 item 9.01

Featured in Daily 8-K Digest

Selected #5 for 2026-06-22. Read digest

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apogee Therapeutics, Inc. entered into Agreement and Plan of Merger with Andor LLC, Andor Merger Co., and AbbVie Inc. valued at $135.11 per Share (effective 2026-06-18).

Action: entry
Agreement: merger
Counterparty: Andor LLC, Andor Merger Co., and AbbVie Inc.
Value: $135.11 per Share
Effective: 2026-06-18

Exact text from the filing

On June 18, 2026, Apogee Therapeutics, Inc. (the “Company” or “Apogee”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Andor LLC, a Delaware limited liability company and a wholly owned subsidiary of Guarantor (“Parent”), Andor Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and solely for the limited purposes set forth therein, AbbVie Inc., a Delaware corporation (“Guarantor” or “AbbVie”).

View on SEC.gov

629 material agreements filed in the last 30 days. Browse all material agreements →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-025844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.